Requires collaboration between stakeholders to develop novel models of funding
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971195 | PMC |
| http://dx.doi.org/10.1136/bmj.39323.586123.BE | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immuno-oncology in the daily practice.
Curr Opin Oncol
January 2025
Gustave Roussy Departement Interdisciplinaire de Soins de Support aux Patients en Onco-hematologie, Villejuif, France.
Purpose Of Review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE).
View Article and Find Full Text PDFOverweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system.
Front Pharmacol
January 2025
Fengxian Hospital, Southern Medical University, Shanghai, China.
Background: In the past few decades, selective serotonin reuptake inhibitors (SSRIs) became widely used antidepressants worldwide. Therefore, the adverse reactions of patients after SSRI administration became a public and clinical concern. In this study, we conducted a pharmacovigilance study using the Adverse Event Reporting System (FAERS) database of the US Food and Drug Administration.
View Article and Find Full Text PDFTheophylline use-a conundrum in modern medicine: a case report.
AME Case Rep
September 2024
Department of Nephrology, Appalachian Regional Healthcare, Harlan, KY, USA.
Background: The theophylline toxidrome presents with multisystemic involvement that includes cardiovascular, neurologic, metabolic, musculoskeletal, and gastrointestinal manifestations. Considering such a varied spectrum of presentations, it is often difficult to ascertain the diagnosis of this particular toxidrome. Review of home medications is an important step when working with a patient presenting as a toxidrome.
View Article and Find Full Text PDFCA-SQBG: Cross-attention guided Siamese quantum BiGRU for drug-drug interaction extraction.
Comput Biol Med
January 2025
College of Electronic Information, Xijing University, Xi'an, China. Electronic address:
Accurate and efficient drug-drug interaction extraction (DDIE) from the medical corpus is essential for pharmacovigilance, drug therapy and drug development. To solve the problems of unbalance dataset and lack of accurate manual annotations in DDIE, a cross-attention guided Siamese quantum BiGRU (CA-SQBG) is constructed to improve feature representation learning ability for DDIE. It mainly consists of two quantum BiGRUs (QBiGRUs) and a cross-attention, where two QBiGRUs are Siamese implemented in a variational quantum environment to learn the contextual semantic feature representation of drug pairs, cross-attention is employed to learn mutual information from the Siamese QBiGRUs, which in turn allows the two modules to extract DDI more collaboratively.
View Article and Find Full Text PDFReal-Time Pharmacovigilance: Transforming Population-Based Monitoring of Post-Approval Vaccine Safety Through Rapid Cycle Analysis (RCA)-A Review of the Published Literature.
Pharmaceuticals (Basel)
January 2025
Safety Surveillance Research, Worldwide Medical and Safety, Pfizer, Inc., New York, NY 10001-2192, USA.
: Rapid cycle analysis (RCA) is an established and efficient methodology that has been traditionally utilized by United States health authorities to monitor post-approval vaccine safety. Initially developed in the Vaccine Safety Datalink (VSD) in early 2000s, RCA has evolved into a valuable approach for timely post-approval signal detection. Due to the availability of additional near real-time data sources and enhanced analytic approaches, the use of RCA has expanded.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!